Roivant Sciences Ltd.
ROIV
Peringkat dalam Saham
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Harga Saham
$33.73
Terakhir disinkronkan: 2026-07-31
Kapitalisasi Pasar
$24.37B
Perubahan (1 hari)
-2.28%
Perubahan (1 tahun)
90.15%
Negara
GB
Perdagangan Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Jumlah saham beredar untuk Roivant Sciences Ltd. (ROIV)
Jumlah saham beredar per June 2026: 720.78M
Menurut laporan keuangan terbaru dan harga saham Roivant Sciences Ltd., jumlah saham beredar saat ini adalah 720.78M. Pada akhir March 2024, perusahaan memiliki 783.25M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Roivant Sciences Ltd. (ROIV) dari 2020 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 720.78M | -0.64% |
| 2025 | 725.40M | -7.39% |
| 2024 | 783.25M | 9.88% |
| 2023 | 712.79M | 6.43% |
| 2022 | 669.75M | -2.20% |
| 2021 | 684.79M | 0.00% |
| 2020 | 684.79M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | -64.77% |
US
|
|
| 396.00M | -45.06% |
US
|
|
| 478.91M | -33.56% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -91.37% |
NL
|
